SPAC merger called off as company connected to ex-Purdue CEO decides to remain private
Sometimes, the third time is not the charm.
Blade Therapeutics announced Monday morning that the company and its proposed merger partner, Biotech Acquisition Company, mutually agreed to call things off, effective immediately. This takes place just seven months after Blade, the small San Francisco biotech where ex-Purdue CEO Mark Timney is board chair, announced the reverse merger worth $254.3 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.